O	0	5	Human	Human	JJ	B-NP
O	6	21	cytomegalovirus	cytomegalovirus	NN	I-NP
O	22	23	5	5	CD	I-NP
O	23	24	-	-	HYPH	I-NP
O	24	32	kilobase	kilobase	NN	I-NP
O	33	42	immediate	immediate	JJ	B-ADJP
O	42	43	-	-	HYPH	O
O	43	48	early	early	JJ	B-NP
O	49	52	RNA	RNA	NN	I-NP
O	53	55	is	be	VBZ	B-VP
O	56	57	a	a	DT	B-NP
O	58	64	stable	stable	JJ	I-NP
O	65	71	intron	intron	NN	I-NP
O	71	72	.	.	.	O

O	73	82	Immediate	Immediate	JJ	B-NP
O	82	83	-	-	HYPH	I-NP
O	83	88	early	early	JJ	I-NP
O	89	94	viral	viral	JJ	I-NP
O	95	99	gene	gene	NN	I-NP
O	100	108	products	product	NNS	I-NP
O	109	111	of	of	IN	B-PP
O	112	117	human	human	JJ	B-NP
O	118	133	cytomegalovirus	cytomegalovirus	NN	I-NP
O	134	135	(	(	(	O
O	135	139	HCMV	HCMV	NN	B-NP
O	139	140	)	)	)	O
O	141	144	are	be	VBP	B-VP
O	145	152	derived	derive	VBN	I-VP
O	153	157	from	from	IN	B-PP
O	158	165	several	several	JJ	B-NP
O	166	173	genomic	genomic	JJ	I-NP
O	174	178	loci	locus	NNS	I-NP
O	179	182	and	and	CC	O
O	183	190	largely	largely	RB	B-VP
O	191	196	serve	serve	VBP	I-VP
O	197	199	to	to	TO	I-VP
O	200	209	establish	establish	VB	I-VP
O	210	211	a	a	DT	B-NP
B-Cell	212	220	cellular	cellular	JJ	I-NP
O	221	232	environment	environment	NN	I-NP
O	233	242	conducive	conducive	VBP	B-VP
O	243	245	to	to	TO	B-PP
O	246	251	viral	viral	JJ	B-NP
O	252	263	replication	replication	NN	I-NP
O	263	264	.	.	.	O

O	265	267	We	We	PRP	B-NP
O	268	272	have	have	VBP	B-VP
O	273	280	further	further	RBR	I-VP
O	281	289	examined	examine	VBN	I-VP
O	290	292	an	an	DT	B-NP
O	293	300	unusual	unusual	JJ	I-NP
O	301	310	immediate	immediate	JJ	I-NP
O	310	311	-	-	HYPH	I-NP
O	311	316	early	early	JJ	I-NP
O	317	327	transcript	transcript	NN	I-NP
O	328	333	known	know	VBN	B-VP
O	334	336	as	as	IN	B-PP
O	337	340	the	the	DT	B-NP
O	341	342	5	5	CD	I-NP
O	342	343	-	-	HYPH	I-NP
O	343	345	kb	kb	NN	I-NP
O	346	349	RNA	RNA	NN	I-NP
O	349	350	,	,	,	O
O	351	361	concluding	conclude	VBG	B-VP
O	362	366	that	that	IN	B-SBAR
O	367	369	it	it	PRP	B-NP
O	370	372	is	be	VBZ	B-VP
O	373	374	a	a	DT	B-NP
O	375	381	stable	stable	JJ	I-NP
O	382	388	intron	intron	NN	I-NP
O	389	396	encoded	encode	VBN	B-VP
O	397	399	by	by	IN	B-PP
O	400	404	HCMV	HCMV	NN	B-NP
O	404	405	.	.	.	O

O	406	409	The	The	DT	B-NP
O	410	411	5	5	CD	I-NP
O	411	412	-	-	HYPH	I-NP
O	412	414	kb	kb	NN	I-NP
O	415	418	RNA	RNA	NN	I-NP
O	419	421	is	be	VBZ	B-VP
O	422	428	highly	highly	RB	B-ADJP
O	429	431	AT	AT	NN	I-ADJP
O	432	436	rich	rich	JJ	I-ADJP
O	437	439	in	in	IN	B-PP
O	440	448	sequence	sequence	NN	B-NP
O	449	452	and	and	CC	O
O	453	458	lacks	lack	VBZ	B-VP
O	459	463	open	open	JJ	B-NP
O	464	471	reading	reading	NN	I-NP
O	472	478	frames	frame	NNS	I-NP
O	479	485	likely	likely	JJ	B-ADJP
O	486	488	to	to	TO	B-VP
O	489	491	be	be	VB	I-VP
O	492	502	translated	translate	VBN	I-VP
O	503	507	into	into	IN	B-PP
O	508	515	protein	protein	NN	B-NP
O	515	516	.	.	.	O

O	517	519	We	We	PRP	B-NP
O	520	529	confirmed	confirm	VBD	B-VP
O	530	533	the	the	DT	B-NP
O	534	541	absence	absence	NN	I-NP
O	542	544	of	of	IN	B-PP
O	545	560	polyadenylation	polyadenylation	NN	B-NP
O	561	563	of	of	IN	B-PP
O	564	567	the	the	DT	B-NP
O	568	578	transcript	transcript	NN	I-NP
O	579	582	and	and	CC	O
O	583	589	showed	show	VBD	B-VP
O	590	594	that	that	IN	B-SBAR
O	595	597	it	it	PRP	B-NP
O	598	600	is	be	VBZ	B-VP
O	601	610	primarily	primarily	RB	B-ADJP
B-Cellular_component	611	618	nuclear	nuclear	JJ	I-ADJP
O	619	628	localized	localize	VBN	B-VP
O	629	635	during	during	IN	B-PP
O	636	641	viral	viral	JJ	B-NP
O	642	651	infection	infection	NN	I-NP
O	651	652	.	.	.	O

O	653	655	We	We	PRP	B-NP
O	656	662	mapped	map	VBD	B-VP
O	663	666	the	the	DT	B-NP
O	667	668	5	5	CD	I-NP
O	668	669	'	'	SYM	I-NP
O	670	673	end	end	NN	I-NP
O	674	676	of	of	IN	B-PP
O	677	680	the	the	DT	B-NP
O	681	682	5	5	CD	I-NP
O	682	683	-	-	HYPH	I-NP
O	683	685	kb	kb	NN	I-NP
O	686	689	RNA	RNA	NN	I-NP
O	690	692	to	to	TO	B-PP
O	693	694	a	a	DT	B-NP
O	695	704	consensus	consensus	NN	I-NP
O	705	711	splice	splice	NN	I-NP
O	712	717	donor	donor	NN	I-NP
O	718	722	site	site	NN	I-NP
O	723	726	and	and	CC	O
O	727	736	localized	localize	VBD	B-VP
O	737	740	the	the	DT	B-NP
O	741	742	3	3	CD	I-NP
O	742	743	'	'	SYM	I-NP
O	744	747	end	end	NN	I-NP
O	748	750	in	in	IN	B-PP
O	751	754	the	the	DT	B-NP
O	755	763	vicinity	vicinity	NN	I-NP
O	764	766	of	of	IN	B-PP
O	767	768	a	a	DT	B-NP
O	769	775	splice	splice	NN	I-NP
O	776	784	acceptor	acceptor	NN	I-NP
O	785	789	site	site	NN	I-NP
O	789	790	.	.	.	O

O	791	793	In	In	IN	B-PP
O	794	806	transfection	transfection	NN	B-NP
O	807	814	studies	study	NNS	I-NP
O	814	815	,	,	,	O
O	816	818	we	we	PRP	B-NP
O	819	825	showed	show	VBD	B-VP
O	826	830	that	that	IN	B-SBAR
O	831	834	the	the	DT	B-NP
O	835	836	5	5	CD	I-NP
O	836	837	-	-	HYPH	I-NP
O	837	839	kb	kb	NN	I-NP
O	840	843	RNA	RNA	NN	I-NP
O	844	847	can	can	MD	B-VP
O	848	850	be	be	VB	I-VP
O	851	858	spliced	splice	VBN	I-VP
O	859	863	from	from	IN	B-PP
O	864	865	a	a	DT	B-NP
O	866	878	heterologous	heterologous	JJ	I-NP
O	879	886	primary	primary	JJ	I-NP
O	887	897	transcript	transcript	NN	I-NP
O	897	898	.	.	.	O

O	899	904	Using	Use	VBG	B-VP
O	905	914	bacterial	bacterial	JJ	B-NP
O	915	925	artificial	artificial	JJ	I-NP
B-Cellular_component	926	936	chromosome	chromosome	NN	I-NP
O	937	947	technology	technology	NN	I-NP
O	947	948	,	,	,	O
O	949	951	we	we	PRP	B-NP
O	952	963	constructed	construct	VBD	B-VP
O	964	965	a	a	DT	B-NP
O	966	971	viral	viral	JJ	I-NP
O	972	983	recombinant	recombinant	NN	I-NP
O	984	994	containing	contain	VBG	B-VP
O	995	996	a	a	DT	B-NP
O	997	1005	mutation	mutation	NN	I-NP
O	1006	1008	in	in	IN	B-PP
O	1009	1012	the	the	DT	B-NP
O	1013	1014	5	5	CD	I-NP
O	1014	1015	'	'	SYM	I-NP
O	1016	1022	splice	splice	NN	I-NP
O	1023	1028	donor	donor	NN	I-NP
O	1029	1033	site	site	NN	I-NP
O	1034	1038	that	that	WDT	B-NP
O	1039	1046	defines	define	VBZ	B-VP
O	1047	1050	the	the	DT	B-NP
O	1051	1052	5	5	CD	I-NP
O	1052	1053	'	'	SYM	I-NP
O	1054	1057	end	end	NN	I-NP
O	1058	1060	of	of	IN	B-PP
O	1061	1064	the	the	DT	B-NP
O	1065	1068	RNA	RNA	NN	I-NP
O	1069	1072	and	and	CC	O
O	1073	1078	found	find	VBD	B-VP
O	1079	1083	that	that	IN	B-SBAR
O	1084	1088	this	this	DT	B-NP
O	1089	1097	mutation	mutation	NN	I-NP
O	1098	1108	eliminates	eliminate	VBZ	B-VP
O	1109	1119	expression	expression	NN	B-NP
O	1120	1122	of	of	IN	B-PP
O	1123	1126	the	the	DT	B-NP
O	1127	1128	5	5	CD	I-NP
O	1128	1129	-	-	HYPH	I-NP
O	1129	1131	kb	kb	NN	I-NP
O	1132	1135	RNA	RNA	NN	I-NP
O	1136	1142	during	during	IN	B-PP
O	1143	1148	viral	viral	JJ	B-NP
O	1149	1158	infection	infection	NN	I-NP
O	1158	1159	.	.	.	O

O	1160	1164	This	This	DT	B-NP
O	1165	1171	mutant	mutant	NN	I-NP
O	1172	1177	grows	grow	VBZ	B-VP
O	1178	1180	in	in	IN	B-PP
O	1181	1186	human	human	JJ	B-NP
B-Cell	1187	1198	fibroblasts	fibroblast	NNS	I-NP
O	1199	1206	without	without	IN	B-PP
O	1207	1222	complementation	complementation	NN	B-NP
O	1222	1223	.	.	.	O

O	1224	1229	Taken	Take	VBN	B-VP
O	1230	1238	together	together	RB	B-ADVP
O	1238	1239	,	,	,	O
O	1240	1245	these	these	DT	B-NP
O	1246	1250	data	datum	NNS	I-NP
O	1251	1258	support	support	VBP	B-VP
O	1259	1262	the	the	DT	B-NP
O	1263	1273	conclusion	conclusion	NN	I-NP
O	1274	1278	that	that	IN	B-SBAR
O	1279	1282	the	the	DT	B-NP
O	1283	1284	5	5	CD	I-NP
O	1284	1285	-	-	HYPH	I-NP
O	1285	1287	kb	kb	NN	I-NP
O	1288	1291	RNA	RNA	NN	I-NP
O	1292	1294	is	be	VBZ	B-VP
O	1295	1296	a	a	DT	B-NP
O	1297	1303	stable	stable	JJ	I-NP
O	1304	1310	intron	intron	NN	I-NP
O	1311	1320	expressed	express	VBN	B-VP
O	1321	1323	by	by	IN	B-PP
O	1324	1328	HCMV	HCMV	NN	B-NP
O	1328	1329	.	.	.	O

